Vaxcyte (PCVX) Stock Price, News & Analysis

Company Overview

Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae. In addition to the pneumococcal program, the company is advancing VAX-A1, a Group A Streptococcus vaccine candidate, and VAX-B4, which targets Group B Streptococcus. These programs are supported by Vaxcyte’s XpressCF+ bioconjugation technology, which uses in vivo bacterial glycoengineering to generate homogeneous conjugate vaccines without the need for separate carrier protein manufacturing steps.

Since its launch in 2018, Vaxcyte has collaborated with academic and industry partners to accelerate its pipeline. The company initiated its initial public offering in August 2020, securing financing to support ongoing clinical trials and technology development. Vaxcyte’s research operations are centered in the San Francisco Bay Area, and the organization is preparing for late-stage clinical studies with the goal of gaining regulatory approvals in the United States and global markets where pneumococcal and streptococcal diseases impose a heavy public health burden.

Vaxcyte is led by a management team with deep expertise in vaccine research, development, and manufacturing. The company continues to expand its scientific capabilities and manufacturing capacity while exploring additional bacterial targets to further extend the benefits of its bioconjugate platform. Through its ongoing clinical programs and platform innovations, Vaxcyte aims to deliver safer, broader-coverage vaccines that address critical gaps in infectious disease prevention.

Key Stats

• Today's Range: $47.00 to $48.37
• 50-Day Range: $47.17 to $62.76
• 52-Week Range: $29.08 to $65.00
• Volume: 1.33 million shs
• Average Volume: 1.69 million shs
• Market Capitalization: $6.83 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $86.00
• Consensus Rating: Moderate Buy

Vaxcyte Stock Analysis - MarketRank™

Vaxcyte scored higher than 56% of companies evaluated by MarketBeat, and ranked 426th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vaxcyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Vaxcyte has a consensus price target of $86.00, representing about 81.8% upside from its current price of $47.30.

Amount of Analyst Coverage

Vaxcyte has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vaxcyte are expected to grow in the coming year, from ($7.85) to ($7.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxcyte is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxcyte is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vaxcyte has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.11% of the float of Vaxcyte has been sold short.

Short Interest Ratio / Days to Cover

Vaxcyte has a short interest ratio ("days to cover") of 13.09, which indicates bearish sentiment.

Change versus previous month

Short interest in Vaxcyte has recently decreased by 1.48%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxcyte does not currently pay a dividend.

Dividend Growth

Vaxcyte does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.66

News Sentiment

Vaxcyte has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Vaxcyte this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for PCVX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $994,899.00 in company stock.

Percentage Held by Insiders

3.10% of the stock of Vaxcyte is held by insiders.

Percentage Held by Institutions

96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/25/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PCVX
• CIK: 1649094
• Web: www.vaxcyte.com
• Phone: 650-837-0111
• Fax: N/A
• Employees: 160
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Vaxcyte: $86.00
• High Price Target: $116.00
• Low Price Target: $38.00
• Potential Upside/Downside: +81.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$766.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.51%
• Return on Assets: -29.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.49
• Quick Ratio: 7.49

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $20.75 per share
• Price / Book: 2.28

Miscellaneous

• Outstanding Shares: 144,400,000
• Free Float: 139,922,000
• Market Cap: $6.83 billion
• Optionable: Optionable
• Beta: 1.30